Clinical trials: Colorectal Cancer, Metastatic
Carcinoma, Colorectal
Phase 1b Dose Escalation Study of Intravenous JX-594 in Metastatic, Refractory Colorectal Carcinoma
The purpose of this pilot safety study is to evaluate the safety and tolerability of JX-594 (Pexa-Vec) administered intravenously every 2 weeks in colorectal carcinoma patients who are refractory to or intolerant of oxaliplatin…
- Trial name
- NCT01380600
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- South Korea
- Volunteers
- 15 people
- Sponsor
- Jennerex Biotherapeutics
BRAF V600E-mutant Metastatic Colorectal Cancer
Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
This is a multicenter, randomized, open-label, 3-arm Phase 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in…
- Trial name
- BEACON CRC (NCT02928224)
- Testing
- Encorafenib, Binimetinib, Cetuximab
- Where
- 418 sites in United States, Argentina and 25 more
- Volunteers
- 702 people
- Sponsor
- Pfizer
Colorectal Neoplasms
Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer
This randomized, open-label, multicenter study will evaluate the efficacy and safety of folinic acid (leucovorin), 5-fluorouracil (5-FU), oxaliplatin, and irinotecan (FOLFOXIRI) / bevacizumab regimens (concurrent and sequential)…
- Trial name
- STEAM (NCT01765582)
- Testing
- 5-fluorouracil, bevacizumab, capecitabine
- Where
- 45 sites in United States
- Volunteers
- 280 people
- Sponsor
- Hoffmann-La Roche
Liver Metastases, Recurrent Colon Cancer
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
RATIONALE: Drugs used in chemotherapy, such as floxuridine and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer
- Trial name
- NCT00645710
- Testing
- gemcitabine hydrochloride, floxuridine, proteomic profiling
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer
Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276861
- Testing
- gemcitabine hydrochloride, oxaliplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Miami
Colorectal Cancer, Screening
Colorectal Cancer: Screening vs. Non-Screening
The purpose of this study is to determine whether colorectal cancer diagnosed by screening (primary screening colonoscopy, colonoscopy after immunochemical based faecal occult blood test) has more favourable clinical-pathological…
- Trial name
- CRC (NCT02727894)
- Where
- Czechia
- Volunteers
- 276 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Colorectal Cancer, Colorectal Carcinoma
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
This study is a randomized multi-center trial that will assess the effect of adding Selective Internal Radiation Therapy (SIRT), using SIR-Spheres microspheres®, to a standard chemotherapy regimen of FOLFOX as first line therapy…
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Liver Metastases
- Trial name
- SIRFLOX (NCT00724503)
- Testing
- SIR-Spheres yttrium-90 microspheres, Systemic chemotherapy (FOLFOX)
- Where
- 111 sites in United States, Australia and 9 more
- Volunteers
- 530 people
- Sponsor
- Sirtex Medical
Metastatic Colorectal Cancer
Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
The purpose of this study is to evaluate the treatment effect of panitumumab plus FOLFIRI compared to FOLFIRI alone as second line therapy for metastatic colorectal cancer.
- Trial name
- NCT00339183
- Testing
- Panitumumab, FOLFIRI
- Volunteers
- 1,186 people
- Sponsor
- Amgen
Metastatic Colorectal Cancer, Colorectal Adenocarcinoma
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
This is a dual arm, open label phase I/II study to evaluate the safety and clinical activity of the combination of durvalumab with CV301 in combination with maintenance chemotherapy for patients with metastatic colorectal or…
- Conditions
- Metastatic Colorectal Cancer, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer
- Trial name
- NCT03376659
- Testing
- Durvalumab, CV301, Capecitabine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Georgetown University
Colorectal Neoplasms
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
The primary objective of this study is to evaluate PFS rate at 9 months of BIBF 1120 in combination with mFolfox6 compared with mFolfox6 combined to bevacizumab in first line patients with metastatic colorectal cancer.
- Trial name
- NCT00904839
- Testing
- BIBF 1120, mFolfox, Bevacizumab
- Where
- 47 sites in Belgium, France and 3 more
- Volunteers
- 128 people
- Sponsor
- Boehringer Ingelheim
Metastatic Colorectal Cancer
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or…
- Trial name
- CheckMate 8HW (NCT04008030)
- Testing
- Ipilimumab, Oxaliplatin, Leucovorin
- Where
- 157 sites in United States, Argentina and 22 more
- Volunteers
- 839 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Adenocarcinoma
Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
This phase III trial studies how well vitamin D3 given with standard chemotherapy and bevacizumab works in treating patients with colorectal cancer that has spread to other parts of the body.
- Trial name
- SOLARIS (NCT04094688)
- Testing
- Bevacizumab, Oxaliplatin, Leucovorin Calcium
- Where
- 1,031 sites in United States, Puerto Rico
- Volunteers
- 455 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Neoplasms
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
This study compares in the first study period combination of Irinotecan with three different methods of administration by Fluoropyrimidine. (ie. infusion, bolus and oral).
- Trial name
- NCT00101686
- Testing
- Modified Bolus 5-FU/LV with Irinotecan, FOLFIRI + bevacizumab, miFL + bevacizumab
- Where
- 175 sites in United States, Australia and 2 more
- Volunteers
- 547 people
- Sponsor
- Pfizer
Solid Tumor, Breast Cancer
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02784795
- Testing
- LY3039478, Taladegib, Abemaciclib
- Where
- 11 sites in United States, Denmark and 2 more
- Volunteers
- 94 people
- Sponsor
- Eli Lilly and Company
Liver Transection During Laparoscopic Liver Resection
Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection
Background: until now, there is no agreement about the safest and feasible method for liver parenchyma transection during laparoscopic liver resection.
- Trial name
- LLS (NCT03208192)
- Testing
- liver transection during laparoscopic liver resection
- Where
- Russia
- Volunteers
- 68 people
- Sponsor
- Moscow Clinical Scientific Center
Colorectal Cancer
An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer
This observational study will evaluate the safety and efficacy of Bevacizumab in combination with 5-Fluorouracil based chemotherapy as first-line and second-line therapy in Chinese participants with metastatic colorectal cancer.
- Trial name
- NCT01319877
- Where
- 24 sites in China
- Volunteers
- 609 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer, Colorectal Neoplasms
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
This is a three-part study of NUC-3373 administered by intravenous (IV) infusion across two administration schedules, either as monotherapy or as part of various combinations with agents commonly used to treat CRC (leucovorin…
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors
- Trial name
- NCT03428958
- Testing
- NUC-3373 + leucovorin, NUC-3373, NUFOX
- Where
- 10 sites in United States, France and 1 more
- Volunteers
- 111 people
- Sponsor
- NuCana plc
Thyroid Cancer, Colon Cancer
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
This is a phase 1b/2 study to evaluate the safety, tolerability, and efficacy of ETBX-011 vaccine used in combination with ALT-803 in subjects with locally advanced or metastatic CEA-expressing cancers whose tumor has recurred…
- Conditions
- Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03127098
- Testing
- ETBX-011, ALT-803
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NantCell, Inc.
Metastatic Colorectal Cancer
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated…
- Trial name
- HORIZON II (NCT00399035)
- Testing
- Cediranib, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), XELOX (Capecitabine and Oxaliplatin)
- Where
- 90 sites in Argentina, Australia and 13 more
- Volunteers
- 1,254 people
- Sponsor
- AstraZeneca
Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of APN401 in treating patients with pancreatic cancer, colorectal cancer, or other solid tumors that have spread to other places in the body or have come back.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma
- Trial name
- NCT03087591
- Testing
- Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wake Forest University Health Sciences